- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01054014
A Single and Multiple Dose Study to Explore the Safety Of JNJ-40346527 In Healthy Volunteers
September 3, 2013 updated by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Double-Blind, Placebo-Controlled, Randomized, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Food Effect, and Pharmacokinetics of JNJ-40346527 in Healthy Subjects
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics (how the drug is absorbed in the body, how it is distributed within the body and it is removed from the body over time) of single and multiple doses of JNJ-40346527 in healthy volunteers.
This study will also investigate the pharmacokinetics of JNJ-40346527 with and without food.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
JNJ-40346527 is an experimental drug that is being tested to see if it may be useful in treating of rheumatoid arthritis and other inflammatory diseases.
This study will compare the effects (both good and bad) of JNJ-40346527 to those of placebo (which looks like the drug being studied but has no active ingredients) in healthy volunteers.
This study will be the first study in which JNJ-40346527 is given to humans.
This study is being conducted in three parts.
Parts 1 and 2 are randomized (study drug will be assigned by chance), double-blind (neither the physician nor volunteer knows the identity of the assigned drug) studies comparing the safety and tolerability of JNJ-40346527 to placebo in 96 healthy volunteers.
Part 3 is an open-label (all people involved know the identity of the assigned drug), 2-period crossover (meaning that volunteers will receive both treatments at different times) study of the effects of food on JNJ-40346527 in 8 healthy male volunteers.
For Part 1, the participation period is a maximum of 64 days, including a screening visit, a 5-day in-clinic period and three follow-up visits.
For Part 2, the participation period is a maximum of 83 days, including a screening visit, an 18-day in-clinic period and two follow-up visits.
For Part 3, the participation period is a maximum of 59 days, including a screening visit, two 4-day in-clinic periods separated by a 7 day break, and a follow-up visit.
For all three parts of the study, safety evaluations, which will include ECG (a cardiac function test), vital signs and monitoring of side-effects will be performed.
Additionally, blood and urine samples will be collected for evaluation.
Volunteers will participate in 1 of 3 parts; Part 1: volunteers will receive a single oral (by mouth) dose of JNJ-40346527 (10, 50, 150, 300, 600, or 1000mg) or placebo; Part 2: volunteers will receive oral doses of JNJ-40346527 (50, 150, 300, 500 or 750mg) or placebo once a day for 14 days; Part 3: volunteers will receive two oral doses of 150mg of JNJ-40346527 with and without food, with a 7-day break between doses.
Study Type
Interventional
Enrollment (Actual)
120
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Antwerp, Belgium
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be generally in good health
- Have negative result for HIV,hepatitis B, and hepatitis C
- Non-smoker for at least 6 months
- Females must be of non childbearing potential,i.e., either: surgically sterile (bilateral tubal ligation or removal of ovaries and/or uterus or partial hysterectomy at least 6 months prior to dosing), or naturally postmenopausal for at least 2 years, with negative blood and urine pregnancy tests prior to dosing
- must consent to use a medically acceptable method of contraception throughout the entire study period and for 90 days after the study is completed
Exclusion Criteria:
- History of alcohol or drug abuse
- Average consumption of more than 5 cups of caffeinated beverages (tea/coffee/cocoa/cola) per day
- History of any type of significant allergies (eg, anaphylaxis, prominent respiratory and skin symptoms)
- Use of St.John's Wort (hypericin) for 30 days before first dosing
- Use of any type of hormone replacement therapy for 30 days before the first dose
- history of receiving a live virus vaccination within the past month or plans to receive vaccination with a live virus vaccine within 2 weeks following the last dose of medication
- receipt of an experimental drug or medical device within the last month
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 001
JNJ-40346527/Placebo Single oral dose of JNJ-40346527 (either 10 50 150 300 600 or 1000mg) or Placebo
|
Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
|
Experimental: 002
JNJ-40346527/Placebo JNJ-40346527 once daily oral dose for 14 days (either 50 150 300 500 or 750mg) or Placebo
|
Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
|
Experimental: 003
JNJ-40346527 JNJ-40346527 150mg one dose either fasting (or with food) then after 7 days off treatment JNJ-40346527 150mg either with food (or fasting)
|
JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the safety, tolerability and pharmacokinetics (PK) of JNJ-40346427 after administration of single and multiple oral ascending doses of JNJ-40346427 in healthy volunteers and the PK of JNJ-4034627 with and without food.
Time Frame: from time of dosing to follow-up (28-35 days)
|
from time of dosing to follow-up (28-35 days)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the pharmacodynamics (explores what the drug does to the body) of JNJ-40346527.
Time Frame: Part 1: Days 1 & 2; Part 2: Days 1, 7, 14, and 15
|
Part 1: Days 1 & 2; Part 2: Days 1, 7, 14, and 15
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2010
Study Completion (Actual)
January 1, 2011
Study Registration Dates
First Submitted
January 21, 2010
First Submitted That Met QC Criteria
January 21, 2010
First Posted (Estimate)
January 22, 2010
Study Record Updates
Last Update Posted (Estimate)
September 4, 2013
Last Update Submitted That Met QC Criteria
September 3, 2013
Last Verified
September 1, 2013
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- CR016795
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Health
-
BIO-CAT Microbials, LLCBiofortis Clinical Research, Inc.CompletedImmune Health | Cardiovascular Health | Gastrointestinal Health | Digestive HealthUnited States
-
Holbaek SygehusRecruitingHealth Behavior | Health Knowledge, Attitudes, Practice | Health-Related Behavior | Health LiteracyDenmark
-
Ankara Yildirim Beyazıt UniversityNot yet recruitingHealth Attitude | Health Behavior | Health KnowledgeTurkey
-
BIO-CAT Microbials, LLCOhio State University; Biofortis Clinical Research, Inc.CompletedImmune Health | Gastrointestinal Health | Digestive HealthUnited States
-
Oregon Health and Science UniversityFederal Emergency Management Agency; National Fallen Firefighters FoundationCompletedHealth Behavior | Occupational Health | Total Worker HealthUnited States
-
Scripps HealthCompletedHealth Attitude | Health Behavior | Health Knowledge, Attitudes, PracticeUnited States
-
Laboratoire Interuniversitaire de Biologie de la...CompletedHealth, Subjective | Health Behavior | Health Knowledge, Attitudes, PracticeFrance
-
Istanbul University - Cerrahpasa (IUC)CompletedHealth Risk Behaviors | Reproductive Health | Sexual HealthTurkey
-
London School of Economics and Political ScienceUniversity of Witwatersrand, South AfricaRecruitingHealth, Subjective | Health Knowledge, Attitudes, Practice | Health Care UtilizationSouth Africa
-
Finnish Institute for Health and WelfareCompletedHealth Behavior | Health Care Utilization | Health Care Seeking BehaviorFinland
Clinical Trials on JNJ-40346527/Placebo
-
University of OxfordJanssen PharmaceuticaUnknownAlzheimer Disease | Mild Cognitive ImpairmentUnited Kingdom
-
Janssen Research & Development, LLCCompletedArthritis, RheumatoidPoland, Ukraine, Chile, Korea, Republic of, Singapore, Russian Federation, Argentina, Bulgaria, Hungary, Czech Republic
-
OHSU Knight Cancer InstituteOregon Health and Science University; Janssen, LP; The Leukemia and Lymphoma...TerminatedRecurrent Acute Myeloid Leukemia | Refractory Acute Myeloid LeukemiaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedProstate Adenocarcinoma | Stage IIIA Prostate Cancer AJCC v8 | Stage IIIB Prostate Cancer AJCC v8 | Stage III Prostate Cancer AJCC v8 | Stage IIIC Prostate Cancer AJCC v8 | Testosterone Greater Than 150 ng/dLUnited States
-
Chengappa, K.N. Roy, MDNational Institutes of Health (NIH)Completed
-
K.N. Roy ChengappaUniversity of Pittsburgh; National Institutes of Health (NIH); Virginia Commonwealth...Completed
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCCompleted
-
Janssen Research & Development, LLCTerminatedAlzheimer DiseaseFrance, Spain, Netherlands, Belgium, Germany, Sweden
-
Janssen Research & Development, LLCCompleted